周三盘中，法国生物技术公司Abivax S.A.（股票代码：ABVX）股价惊人暴涨547%，引发市场轰动。这一戏剧性涨幅背后，是该公司在溃疡性结肠炎治疗领域取得的重大突破。
据悉，Abivax的口服溃疡性结肠炎新药obefazimod在两项大型三期临床试验（ABTECT-1和ABTECT-2）中取得了积极结果。试验显示，obefazimod在治疗8周后，在实现临床缓解方面明显优于安慰剂，其中25mg和50mg剂量组分别实现了13.2%和16.4%的统计显著差异（p＜0.0001）。值得注意的是，这项试验纳入了大比例此前对其他先进疗法无响应的患者，凸显了obefazimod的潜在价值。
这一突破性进展不仅为溃疡性结肠炎患者带来新的治疗希望，也极大地提升了投资者对Abivax前景的信心。作为一家仅有约70名员工的小型生物技术公司，Abivax此前面临着资金紧张的困境。然而，随着obefazimod的成功，公司的融资能力有望大幅提升。业内专家认为，这一结果可能彻底改变Abivax的命运，甚至引发大型制药公司的收购兴趣。obefazimod独特的作用机制和广阔的市场前景，使其有潜力成为炎症性肠病（IBD）治疗领域的重要参与者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.